Omg.... we gotta have msnbc covering the Brits all morning like it was the friggin' OJ chase?! As I type they are updating the fate of her Corgi's. Pretty sure they'll be just fine. Isn't today 9/11? >>>"Never Forget!" <<<
I wish they would talk a little more about the Queen's favorite horse.- Burmese, born in Saskatchewan and trained in Ottawa, might have even saved her life when an assassin opened fire in 1981 in London
That's one of their pipeline drugs. ROLVEDON™ is the one that just got approved. Phase 3 had 643 patients: "which evaluated the safety and efficacy of ROLVEDON in 643 early-stage breast cancer patients for the management of neutropenia due to myelosuppressive chemotherapy." https://www.sppirx.com/300-spectrum-products-portfolio.html
On the regulatory front, we expect the US Inflation Reduction Act should provide significant upside to Fluence in the coming years. One of the key provisions of the bill is a 30% standalone storage investment tax credit. We also see other benefits resulting from the bill, which I will discuss shortly. As a reminder, our financial plans have not assumed these tax credits or other incentives. As we announced earlier this month, we have established a contract manufacturing location in Utah, which is expected to start production in late September. This will enable us to finalize assembly of our products here in the United States, closer to our customer sites. This will also allow us to avoid some of the supply chain issues we have encountered in other locations. More importantly, we expect to be able to capitalize on some of the incentives provided under the Inflation Reduction Act for our Utah facility.
new CEO- Julian Nebreda Thank you, Manuel. It is an honor and a privilege to be here with you today. Although I do not become CEO until September 1st, I thought I would share with you a bit about my background and my initial thoughts and priorities for Fluence. I'm not new to the Fluence family as I have been involved with the company since its creation and have been on the Fluence Board for the past year. For the past 23 years, I have served around the globe in different leadership roles for AES. Most recently, I was President of AES U.S. and global business lines. I have a kin interest and experience in growing renewable businesses. And I am proud to have led AES Europe when we introduced the first battery and e-storage projects units there. I have a good understanding of the key issues for Fluence from my role as a director. Although I'm still getting up to speed on the details of Fluence day-to-day operations, at this time, I do not foresee any major changes to Fluence strategy.
Oh that one -- very toxic. It doesn't cure cancer it's just for infections and for less infection you get-- YOUR SPLEEN RUPTURED!> Spleen rupture Splenic rupture, including fatal cases, may occur following administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) products. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. Acute Respiratory Distress Syndrome (ARDS)- Oh good that's fun ARDS may occur in patients receiving rhG-CSF products. Evaluate patients who develop fever, pulmonary infiltrates, or respiratory distress. Discontinue ROLVEDON in patients with ARDS. Severe allergic reactions - Why Not! Serious allergic reactions, including anaphylaxis, may occur in patients receiving rhG-CSF products. Permanently discontinue ROLVEDON in patients who experience severe allergic reactions. Sickle cell crisis in patients with sickle cell disorders Glomerulonephritis- I have no idea but bring it on! Glomerulonephritis has occurred in patients receiving rhG-CSF products. Diagnoses were based on azotaemia, hematuria (microscopic and macroscopic), proteinuria and renal biopsy. Events of glomerulonephritis generally resolved after dose reduction or discontinuation. Evaluate and consider dose reduction or discontinuation of ROLVEDON if causality is likely. Leukocytosis Thrombocytopenia Capillary leak syndrome-> of course! Capillary leak syndrome has been reported following administration of rhG-CSF products and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Episodes vary in frequency and severity and can be life-threatening if treatment is delayed. If symptoms develop, monitor closely and provide standard symptomatic treatment, which may include the need for intensive care. Potential for tumor growth-stimulating effects on malignant cells<-- WHAT!!!!!! The granulocyte colony-stimulating factor (G-CSF) receptor through which ROLVEDON works has been found on tumor cell lines. The possibility that ROLVEDON acts as a growth factor for any tumor type, including myeloid malignancy and myelodysplasia, diseases for which ROLVEDON is not approved, cannot be excluded. Christ no infection but sorry your breast cancer is much worse now.... Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer Aortitis Aortitis has been reported in patients receiving rhG-CSF products. It can occur as early as the first week after starting treatment. Consider aortitis in patients who develop generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and elevated inflammatory markers (eg, c-reactive protein and white blood cell count) without known etiology. Discontinue ROLVEDON if aortitis is suspected. Nuclear imaging Side effects The most common adverse reactions (≥20%) were fatigue, nausea, diarrhea, bone pain, headache, pyrexia, anemia, rash, myalgia, arthralgia, and back pain. back pain too... no.